Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report ; volume:19 ; number:1 ; day:11 ; month:6 ; year:2019 ; pages:1-5 ; date:12.2019
BMC cancer ; 19, Heft 1 (11.6.2019), 1-5, 12.2019
- Creator
-
Callebout, Eduard
Ribeiro, Suzane Moura
Laurent, Stephanie
De Man, Marc
Ferdinande, Liesbeth
Claes, Kathleen B. M.
Van der Meulen, Joni
Geboes, Karen P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-5763-5
- URN
-
urn:nbn:de:101:1-2019110506022078962027
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Callebout, Eduard
- Ribeiro, Suzane Moura
- Laurent, Stephanie
- De Man, Marc
- Ferdinande, Liesbeth
- Claes, Kathleen B. M.
- Van der Meulen, Joni
- Geboes, Karen P.
- SpringerLink (Online service)
Other Objects (12)
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie